| P50 | author | Markus Rehm | Q42674464 |
| | Jasper Wouters | Q54368854 |
| P2093 | author name string | Claudia Aura | |
| | Joost J van den Oord | |
| | Madhuri Warren | |
| | William M Gallagher | |
| | Mairin Rafferty | |
| | Jesuchristopher Joseph | |
| | Emilie M Charles | |
| | Ciaran de Chaumont | |
| | Peter Dynoodt | |
| | Arman Rahman | |
| | Cristiano Guttà | |
| | Elodie Hirschenhahn | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. | Q41129712 |
| | Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia | Q43203445 |
| | High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). | Q43889031 |
| | BCL-2 expression is prognostic for improved survival in non-small cell lung cancer | Q46200246 |
| | BCL-2 family proteins: changing partners in the dance towards death | Q47155532 |
| | Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. | Q47791534 |
| | Bcl-2 is a useful prognostic marker in Dukes' B colon cancer | Q49282314 |
| | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. | Q52602395 |
| | Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. | Q53328861 |
| | Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. | Q53424806 |
| | Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). | Q53950965 |
| | Melanoma treatment in review. | Q55217220 |
| | ZBP-89 and Sp1 contribute to Bak expression in hepatocellular carcinoma cells. | Q55383942 |
| | Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond | Q57162853 |
| | Bromodomain‑containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein | Q61815612 |
| | Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas | Q73121445 |
| | Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer | Q73190404 |
| | Expression of apoptosis regulators in cutaneous malignant melanoma | Q77151107 |
| | Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings | Q79779728 |
| | Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis | Q80210089 |
| | Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy | Q80624789 |
| | Clinical significance of Smac/DIABLO expression in colorectal cancer | Q83196062 |
| | Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients | Q84537482 |
| | Counting on Death - Quantitative aspects of Bcl-2 family regulation | Q88785525 |
| | The role for chemotherapy in the modern management of melanoma | Q91323544 |
| | Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 |
| | Toward a Shared Vision for Cancer Genomic Data | Q26966456 |
| | How cell death shapes cancer | Q27021441 |
| | Prognostic significance of smac/DIABLO in endometrioid endometrial cancer | Q28308297 |
| | Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma | Q28378420 |
| | High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel | Q28548522 |
| | Mitochondria and cell death: outer membrane permeabilization and beyond | Q29615459 |
| | Apoptosis: controlled demolition at the cellular level | Q29620114 |
| | Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells | Q30549646 |
| | Inactivation of the apoptosis effector Apaf-1 in malignant melanoma | Q31984891 |
| | Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis | Q33236007 |
| | High Smac/DIABLO expression is associated with early local recurrence of cervical cancer | Q33261665 |
| | Treatments for metastatic melanoma: synthesis of evidence from randomized trials | Q33301788 |
| | Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group | Q33372613 |
| | Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy | Q33610993 |
| | Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c | Q34600089 |
| | Genomic Classification of Cutaneous Melanoma | Q34670776 |
| | Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy | Q35093740 |
| | Apoptosis and melanoma chemoresistance | Q35146577 |
| | Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. | Q35748569 |
| | The prognostic influence of bcl-2 in malignant glioma | Q36644672 |
| | Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen | Q36648786 |
| | Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology | Q36931849 |
| | SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells | Q37695388 |
| | Biomarkers as prognostic factors in endometrial cancer | Q37808862 |
| | The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies. | Q37824333 |
| | Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. | Q38172752 |
| | The Systemic Management of Advanced Melanoma in 2016. | Q38814258 |
| | Key regulators of apoptosis execution as biomarker candidates in melanoma | Q38866722 |
| | A fate worse than death: apoptosis as an oncogenic process | Q38882537 |
| | The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma | Q38909389 |
| | Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. | Q39244850 |
| | Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment | Q39661214 |
| | Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis | Q40245914 |
| | "Bak (and Bax) to the future"--of primary melanoma prognosis? | Q40325034 |
| | X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells | Q40559201 |
| | Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo | Q40559712 |
| P433 | issue | 2 | |
| P921 | main subject | apoptotic process | Q14599311 |
| | metastatic melanoma | Q18975855 |
| P304 | page(s) | 124 | |
| P577 | publication date | 2020-02-13 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma | |
| P478 | volume | 11 | |